心脏移植受者的结直肠癌:竞争风险分析。

IF 3.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Alan Abboud, Amin Tajerian, Sharon Charles, Michael Clores, Marc Goldschmidt, Olga Aroniadis, Andreas Kalogeropoulos
{"title":"心脏移植受者的结直肠癌:竞争风险分析。","authors":"Alan Abboud, Amin Tajerian, Sharon Charles, Michael Clores, Marc Goldschmidt, Olga Aroniadis, Andreas Kalogeropoulos","doi":"10.1111/eci.70107","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Data on colorectal cancer (CRC) risk in heart transplant (HT) patients are limited, and screening recommendations specific to this population, especially patients under age 45, are lacking. We aimed to assess the incidence of post-HT CRC, with a focus on the effect of age.</p><p><strong>Methods: </strong>Using data from the TriNetX Research Network, we identified 4516 adults (≥18 years) who received HT between 1996 and 2024 in the United States, based on CPT codes for HT (33945) and combined lung-HT (33935). CRC was identified from ICD-10 CM codes (C18, C19, & C20). Because mortality was higher than CRC risk, we used a competing risks framework to estimate CRC incidence.</p><p><strong>Results: </strong>After a median follow-up of 3.6 years (25th-75th percentile, 1.4-6.7), 48 patients developed CRC. Median time from HT to CRC was 4.5 years (.7-8.0). The cumulative incidence of CRC was 1.73% (CI: 1.22%-2.45%) at 10 years, corresponding to 173/100,000 person-years. In comparison, the United States age-adjusted general population rate was 36.5/100,000 between 2016 and 2020. Age at HT was not significantly associated with CRC risk (p = .22); patients age < 45 at HT experienced similar risk as patients ≥45. The CRC risk difference between men and women was not significant (1.89% vs. 1.23% at 10 years; p = .74). All-cause mortality was 20.4% at 5 years and 38.8% at 10 years.</p><p><strong>Conclusions: </strong>In this HT cohort, CRC risk was markedly higher compared to the general population and did not differ by age, suggesting that HT recipients may require screening for CRC regardless of age.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70107"},"PeriodicalIF":3.6000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Colorectal cancer in heart transplant recipients: A competing risk analysis.\",\"authors\":\"Alan Abboud, Amin Tajerian, Sharon Charles, Michael Clores, Marc Goldschmidt, Olga Aroniadis, Andreas Kalogeropoulos\",\"doi\":\"10.1111/eci.70107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Data on colorectal cancer (CRC) risk in heart transplant (HT) patients are limited, and screening recommendations specific to this population, especially patients under age 45, are lacking. We aimed to assess the incidence of post-HT CRC, with a focus on the effect of age.</p><p><strong>Methods: </strong>Using data from the TriNetX Research Network, we identified 4516 adults (≥18 years) who received HT between 1996 and 2024 in the United States, based on CPT codes for HT (33945) and combined lung-HT (33935). CRC was identified from ICD-10 CM codes (C18, C19, & C20). Because mortality was higher than CRC risk, we used a competing risks framework to estimate CRC incidence.</p><p><strong>Results: </strong>After a median follow-up of 3.6 years (25th-75th percentile, 1.4-6.7), 48 patients developed CRC. Median time from HT to CRC was 4.5 years (.7-8.0). The cumulative incidence of CRC was 1.73% (CI: 1.22%-2.45%) at 10 years, corresponding to 173/100,000 person-years. In comparison, the United States age-adjusted general population rate was 36.5/100,000 between 2016 and 2020. Age at HT was not significantly associated with CRC risk (p = .22); patients age < 45 at HT experienced similar risk as patients ≥45. The CRC risk difference between men and women was not significant (1.89% vs. 1.23% at 10 years; p = .74). All-cause mortality was 20.4% at 5 years and 38.8% at 10 years.</p><p><strong>Conclusions: </strong>In this HT cohort, CRC risk was markedly higher compared to the general population and did not differ by age, suggesting that HT recipients may require screening for CRC regardless of age.</p>\",\"PeriodicalId\":12013,\"journal\":{\"name\":\"European Journal of Clinical Investigation\",\"volume\":\" \",\"pages\":\"e70107\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-08-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/eci.70107\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.70107","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:关于心脏移植(HT)患者结直肠癌(CRC)风险的数据有限,并且缺乏针对这一人群的筛查建议,特别是45岁以下的患者。我们的目的是评估ht后CRC的发病率,重点关注年龄的影响。方法:使用TriNetX研究网络的数据,基于HT(33945)和联合肺部HT(33935)的CPT代码,我们确定了1996年至2024年间在美国接受HT治疗的4516名成年人(≥18岁)。从ICD-10 CM代码(C18、C19和C20)中鉴定出CRC。由于死亡率高于CRC风险,我们使用竞争风险框架来估计CRC发病率。结果:中位随访3.6年(25 -75百分位,1.4-6.7)后,48例患者发展为结直肠癌。从HT到结直肠癌的中位时间为4.5年(0.7 -8.0)。10年时CRC的累积发病率为1.73% (CI: 1.22%-2.45%),相当于173/100,000人年。相比之下,2016年至2020年期间,美国年龄调整后的一般人口比率为36.5/10万。年龄与结直肠癌风险无显著相关性(p = 0.22);结论:在这个HT队列中,与一般人群相比,CRC风险明显更高,并且没有年龄差异,这表明无论年龄如何,接受HT治疗的患者都可能需要筛查CRC。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Colorectal cancer in heart transplant recipients: A competing risk analysis.

Background: Data on colorectal cancer (CRC) risk in heart transplant (HT) patients are limited, and screening recommendations specific to this population, especially patients under age 45, are lacking. We aimed to assess the incidence of post-HT CRC, with a focus on the effect of age.

Methods: Using data from the TriNetX Research Network, we identified 4516 adults (≥18 years) who received HT between 1996 and 2024 in the United States, based on CPT codes for HT (33945) and combined lung-HT (33935). CRC was identified from ICD-10 CM codes (C18, C19, & C20). Because mortality was higher than CRC risk, we used a competing risks framework to estimate CRC incidence.

Results: After a median follow-up of 3.6 years (25th-75th percentile, 1.4-6.7), 48 patients developed CRC. Median time from HT to CRC was 4.5 years (.7-8.0). The cumulative incidence of CRC was 1.73% (CI: 1.22%-2.45%) at 10 years, corresponding to 173/100,000 person-years. In comparison, the United States age-adjusted general population rate was 36.5/100,000 between 2016 and 2020. Age at HT was not significantly associated with CRC risk (p = .22); patients age < 45 at HT experienced similar risk as patients ≥45. The CRC risk difference between men and women was not significant (1.89% vs. 1.23% at 10 years; p = .74). All-cause mortality was 20.4% at 5 years and 38.8% at 10 years.

Conclusions: In this HT cohort, CRC risk was markedly higher compared to the general population and did not differ by age, suggesting that HT recipients may require screening for CRC regardless of age.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.50
自引率
3.60%
发文量
192
审稿时长
1 months
期刊介绍: EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信